Hydrochloric Acid

Hydrochloric Acid

SCHEMBL1329672

CCCCCCCCCCCCCCCC(C)NCc1ccccc1.Cl

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SIGMAR1 known ✓ Q99720 3/20 0.56
BCHE known ✓ P06276 1/20 0.48
GAA known ✓ P10253 1/20 0.44
TLR2 O60603 4/20 0.49
EPHX2 P34913 1/20 0.46
CSNK1E P49674 1/20 0.45
CNR2 P34972 1/20 0.44
ATM Q13315 1/20 0.44
POLB P06746 2/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1330333 1.00 SIGMAR1 (0.56) SIGMAR1TLR2BCHEEPHX2CSNK1E
Hydrochloric Acid SCHEMBL11272545 1.00 SIGMAR1 (0.56) SIGMAR1TLR2BCHEEPHX2CSNK1E
Hydrochloric Acid SCHEMBL5925639 1.00 SIGMAR1 (0.56) SIGMAR1TLR2BCHEEPHX2CSNK1E
SCHEMBL667265 0.98 SIGMAR1 (0.58) SIGMAR1TLR2BCHEEPHX2CSNK1E
SCHEMBL666714 0.98 SIGMAR1 (0.58) SIGMAR1TLR2BCHEEPHX2CSNK1E
SCHEMBL19868618 0.98 SIGMAR1 (0.58) SIGMAR1TLR2BCHEEPHX2CSNK1E
SCHEMBL27919164 0.98 SIGMAR1 (0.58) SIGMAR1TLR2BCHEEPHX2CSNK1E
Bromide SCHEMBL1330662 0.97 SIGMAR1 (0.56) SIGMAR1TLR2BCHEEPHX2CSNK1E
Bromide SCHEMBL1330640 0.97 SIGMAR1 (0.56) SIGMAR1TLR2BCHEEPHX2CSNK1E
SCHEMBL2794487 0.97 SIGMAR1 (0.59) SIGMAR1TLR2BCHEEPHX2CSNK1E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962662-B2 Antimicrobial compositions and methods of use thereof BYOCOAT ENTERPRISES, INC. (US) 2015-02-24 US disclosed
US-8586115-B2 Antimicrobial solutions and process related thereto BYOCOAT ENTERPRISES, INC. (US) 2013-11-19 US disclosed
US-20130137732-A1 ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF BYOCOAT ENTERPRISES, INC. (US) 2013-05-30 US disclosed
WO-2013074526-A2 ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF BYOCOAT ENTERPRISES, INC. (US) 2013-05-23 WO disclosed
US-20120264758-A1 ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO BYOCOAT ENTERPRISES, INC. (US) 2012-10-18 US disclosed
CN-101316516-B Antimicrobial solutions and methods relating thereto BYOCOAT ENTPR INC 2012-05-30 CN disclosed
US-20110281002-A1 ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO BYOCOAT ENTERPRISES, INC. (PR) 2011-11-17 US disclosed
CN-102083313-A Compositions and methods for reducing or preventing microorganism growth or survival in aqueous environments BYOCOAT ENTPR INC 2011-06-01 CN disclosed
US-20090192165-A1 ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO BYOCOAT ENTERPRISES, INC. (PR) 2009-07-30 US disclosed
CN-101316516-A Antimicrobial solutions and methods relating thereto BYOCOAT ENTPR INC (US) 2008-12-03 CN disclosed
EP-1931209-A1 ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO Byocoat Enterprises, Inc. (US) 2008-06-18 EP disclosed
WO-2008008362-A2 COMPOSITIONS AND METHODS FOR REDUCING OR PREVENTING MICROORGANISM GROWTH OR SURVIVAL IN AQUEOUS ENVIRONMENTS BYOCOAT ENTERPRISES, INC. (US) 2008-01-17 WO disclosed
WO-2007030104-A1 ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO BYOCOAT ENTERPRISES, INC. (US) 2007-03-15 WO disclosed
US-20060110506-A1 Antimicrobial solutions and process related thereto BYOCOAT ENTERPRISES, INC. 2006-05-25 US disclosed
US-20050271781-A1 Antimicrobial solutions and process related thereto BYOCOAT ENTERPRISES, INC. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137732-A1 ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF KARS1, AAAS, AARS1 SIGMAR1 793/4885BCHE 906/4885GAA 350/4885
US-20110281002-A1 ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO DAO, AGPS, TH SIGMAR1 509/4885BCHE 256/4885GAA 642/4885
US-20090192165-A1 ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO DAO, AGPS, DDC SIGMAR1 955/4885BCHE 470/4885GAA 711/4885
US-20120264758-A1 ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO DAO, AGPS, DDC SIGMAR1 955/4885BCHE 470/4885GAA 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.